CHE vs. LH, DGX, DVA, RCM, CRVL, AMED, AMN, MD, CCRN, and OPCH
Should you be buying Chemed stock or one of its competitors? The main competitors of Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), R1 RCM (RCM), CorVel (CRVL), Amedisys (AMED), AMN Healthcare Services (AMN), Pediatrix Medical Group (MD), Cross Country Healthcare (CCRN), and Option Care Health (OPCH).
Chemed (NYSE:CHE) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Chemed has a net margin of 12.88% compared to Laboratory Co. of America's net margin of 3.52%. Chemed's return on equity of 29.90% beat Laboratory Co. of America's return on equity.
Chemed pays an annual dividend of $1.60 per share and has a dividend yield of 0.3%. Laboratory Co. of America pays an annual dividend of $2.88 per share and has a dividend yield of 1.4%. Chemed pays out 8.6% of its earnings in the form of a dividend. Laboratory Co. of America pays out 57.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Chemed has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
95.9% of Chemed shares are owned by institutional investors. Comparatively, 95.9% of Laboratory Co. of America shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 0.9% of Laboratory Co. of America shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Laboratory Co. of America has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.
In the previous week, Chemed had 5 more articles in the media than Laboratory Co. of America. MarketBeat recorded 18 mentions for Chemed and 13 mentions for Laboratory Co. of America. Laboratory Co. of America's average media sentiment score of 0.79 beat Chemed's score of 0.42 indicating that Laboratory Co. of America is being referred to more favorably in the news media.
Laboratory Co. of America received 273 more outperform votes than Chemed when rated by MarketBeat users. Likewise, 64.08% of users gave Laboratory Co. of America an outperform vote while only 63.46% of users gave Chemed an outperform vote.
Chemed currently has a consensus price target of $673.50, suggesting a potential upside of 22.33%. Laboratory Co. of America has a consensus price target of $241.29, suggesting a potential upside of 14.10%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Laboratory Co. of America.
Summary
Chemed and Laboratory Co. of America tied by winning 10 of the 20 factors compared between the two stocks.
Get Chemed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
